Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc.
Your view on LIXTW
Overview
What the company does, where it operates, and who runs it.
About Lixte Biotechnology Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geordan G. Pursglove
- Headquarters
- 680 East Colorado Boulevard, Pasadena, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geordan G. Pursglove
- Headquarters
- 680 East Colorado Boulevard, Pasadena, CA, US
Lixte Biotechnology Holdings, Inc. functions as a biopharmaceutical firm dedicated to the discovery and development of innovative therapeutic compounds. The company leverages advanced biomarker technology to create novel drug candidates aimed at combating severe and widespread human diseases. Its core research primarily concentrates on protein phosphatase inhibitors, which are being explored for standalone administration or in conjunction with cytotoxic agents, radiation therapy, and immune checkpoint blockers. The company's developmental pipeline includes two distinct series of pharmacologically active agents, both progressing through various preclinical and clinical phases. The LB-100 series comprises new chemical entities designed to address cancers, vascular ailments, and metabolic disorders. Meanwhile, the LB-200 series is being developed to treat chronic hereditary conditions, such as Gaucher's disease, alongside certain types of cancer and neurodegenerative illnesses. Lixte Biotechnology Holdings, Inc. maintains significant research collaborations, including a clinical trial agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. It also has partnership agreements for investigator-initiated clinical trials with the Spanish Sarcoma Group, as well as the Netherlands Cancer Institute and Oncode Institute. Established in 2005, the company's headquarters are located in Pasadena, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Lixte Biotechnology Holdings, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lixte Biotechnology Holdings, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lixte Biotechnology Holdings, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lixte Biotechnology Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lixte Biotechnology Holdings, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lixte Biotechnology Holdings, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Lixte Biotechnology Holdings, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Lixte Biotechnology Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lixte Biotechnology Holdings, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lixte Biotechnology Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lixte Biotechnology Holdings, Inc.. Press releases and market coverage, newest first.